US Patent Issued to Alnylam Pharmaceuticals on Feb. 24 for "Compositions and methods for inhibiting expression of TMPRSS6 gene" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,755, issued on Feb. 24, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Compositions and methods for inhibiting expression of TMPRSS6 gene" was invented by David Bumcrot (Cambridge, Mass.), Brian Bettencourt (Groton, Mass.) and Ivanka Toudjarska (Medford, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6."

The patent was filed on Sept. 28, 2023, under Application No. 18/374,166.

*For further information, including images, charts and tables, plea...